

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  A61K		A2	(11) International Publication Number: <b>WO 93/10747</b>  (43) International Publication Date: 10 June 1993 (10.06.93)
(21) International Application Number: PCT/US92/10716  (22) International Filing Date: 19 November 1992 (19.11.92)		(81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).  Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority data: 807,062 27 November 1991 (27.11.91) US			
(71) Applicant: DIATECH, INC. [US/US]; 9 Delta Drive, Londonderry, NH 03053 (US).			
(72) Inventors: DEAN, Richard, T. ; 43 King Road, Bedford, NH 03110 (US). McBRIDE, William ; 110 Golfview Drive, Manchester, NH 03102 (US). BUTTRAM, Scott ; 12 Gervaise Drive, Derry, NH 03038 (US).			
(74) Agent: NOONAN, Kevin, E; Allegretti & Witcoff, Ltd., Ten South Wacker Drive, Chicago, IL 60606 (US).			

**(54) Title: TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING****(57) Abstract**

The invention relates to radiolabeled imaging of a mammalian body. The invention in particular provides for reagents labeled with technetium-99m for such imaging. The invention provides peptides which bind Tc-99m and which can be targeted to specific sites within a mammalian body.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BI	Burundi	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Macao	TG	Togo
DE	Germany	MD	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

## TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING

## BACKGROUND OF THE INVENTION

5 1. Field of the Invention

This invention relates to radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (Tc-99m) labeled reagents, methods and kits for making such reagents, and methods for using such reagents. In 10 particular, the invention relates to Tc-99m labeled peptides comprised of between 4 and 100 amino acid residues and covalently linked to a radioisotope complexing group.

15 2. Description of the Prior Art

The use of chelating agents for radiolabeling polypeptides is known in the prior art.

Byrne *et al.*, U.S. Patent No. 4,434,151 describe homocysteine thiolactone bifunctional chelating agents that can couple radionuclides to terminal amino-containing compounds capable of localizing in an organ or 20 tissue to be imaged.

Fritzberg, U.S. Patent No. 4,444,690 describes a series of technetium-chelating agents based on 2,3-bis(mercaptoacetamido) propanoate.

Gansow *et al.*, U.S. Patent No. 4,472,509 teach methods of manufacturing and purifying metal chelate-conjugated monoclonal antibodies.

Byrne *et al.*, U.S. Patent Nos. 4,571,430 and 4,575,556 describe novel homocysteine thiolactone bifunctional chelating agents for chelating radionuclides that can couple radionuclides to terminal amino-containing compounds capable of localizing in an organ or tissue to be imaged.

Nicolotti *et al.*, U.S. Patent No. 4,861,869 describe bifunctional coupling agents useful in forming conjugates with biological molecules such as antibodies. This reference describes compounds such as S-benzoylmercaptoacetylglycylglycylglycine.

European Patent Application No. 84109831.2 describes technetium

chelating complexes of bisamido-bisthio-ligands and salts thereof, used primarily as renal function monitoring agents.

5 European Patent Application No. 86100360.6 describes dithiol, diamino, or diamidocarboxylic acids or amine complexes useful for making technetium imaging agents.

European Patent Application No. 88104755.9 describes various S-protected mercaptoacetylglycylglycine chelating groups bound to large proteins such as antibodies.

10 Albert *et al.*, UK Patent Application No. 8927255.3 disclose radioimaging using somatostatin derivatives such as octreotide labeled with  $^{111}\text{In}$  via a chelating group bound to the amino terminus.

Flanagan *et al.*, European Patent Application No. 90306428.5 disclose Tc-99m labeling synthetic peptide fragments via a set of organic chelating molecules.

15 Albert *et al.*, European Patent Application No. WO 91/01144 disclose radioimaging using radiolabeled peptides related to growth factors, hormones, interferons and cytokines and comprised of a specific recognition peptide covalently linked to a radionuclide chelating group.

20 Davison *et al.*, Inorg. Chem. 20: 1629-1632 (1981) disclose oxotechnetium chelate complexes.

Fritzberg *et al.*, J. Nucl. Med. 23: 592-598 (1982) disclose a technetium chelating agent based on N,N'-bis(mercaptopropyl)-2,3-diaminopropanoate.

25 Byrne and Tolman, J. Nucl. Med. 24: P126 (1983) disclose a bifunctional thiolactone chelating agent for coupling Tc-99m to biological molecules.

Bryson *et al.*, Inorg. Chem. 27: 2154-2161 (1988) describe thiolate ligands for complexing with technetium.

30 Bryson *et al.*, Inorg. Chem. 29: 2948-2951 (1990) describe thiolate ligands for complexing with technetium.

Kwekkeboom *et al.*, J. Nucl. Med. 32: 981 (1991) Abstract #305 relates to radiolabeling somatostatin analogues with  $^{111}\text{In}$ .

Albert *et al.*, Abstract LM10, 12th American Peptide Symposium (1991) describe uses for  $^{111}\text{In}$ -labeled diethylenetriaminopentaacetic acid-derivatized somatostatin analogues.

5 A variety of radionuclides are known to be useful for radioimaging, including  $^{67}\text{Ga}$ ,  $^{99m}\text{Tc}$  (Tc-99m),  $^{111}\text{In}$ ,  $^{123}\text{I}$ ,  $^{125}\text{I}$ ,  $^{166}\text{Yb}$  or  $^{186}\text{Re}$ . The sensitivity of imaging methods using radioactively-labeled peptides is much higher than other techniques known in the art, since the specific binding of the radioactive peptide concentrates the radioactive signal over the cells of interest, for example, tumor cells.

10 Methods for labeling peptides and polypeptides with Tc-99m have been disclosed in the prior art.

15 Dean, co-pending U.S. Patent Application Serial No. 07/653,012 teaches reagents and methods for preparing peptides comprising a Tc-99m chelating group covalently linked to a specific binding peptide for radioimaging *in vivo*, and is hereby incorporated by reference.

Fritzberg, U.S. Patent No. 4,444,690 describes a series of technetium-chelating agents based on 2,3-bis(mercaptoacetamido)propanoate.

20 Gansow *et al.*, U.S. Patent No. 4,472,509 teach methods of manufacturing and purifying Tc-99m chelate-conjugated monoclonal antibodies.

Reno and Bottino, European Patent Application No. 87300426.1 disclose radiolabeling antibodies with Tc-99m.

25 Bremer *et al.*, EPC Application No. 87118142.6 disclose organ-specific radioimaging using Tc-99M radiolabeled proteins.

Pak *et al.*, European Patent Application No. WO 88/07382 disclose a method for labeling antibodies with Tc-99m.

30 Goedemans *et al.*, PCT Application No. WO 89/07456 describe radiolabeling proteins using cyclic thiol compounds, particularly on 2-iminothiolane and derivatives.

Schochat *et al.*, PCT Application No. WO 89/09405 disclose direct radiolabeling of proteins comprised of at least one "pendent" sulphydryl group.

Dean *et al.*, PCT Application No. WO 89/12625 describe bifunctional

coupling agents for Tc-99m labeling of proteins or peptides.

Thornback *et al.*, EPC Application No. 90402206.8 describe preparation and use of radiolabeled proteins or peptides using thiol-containing compounds, particularly 2-iminothiolane.

5 Stuttle, PCT Application No. WO 90/15818 describes Tc-99m labeling of RGD-containing oligopeptides.

Rhodes, Sem. Nucl. Med. 4: 281-293 (1974) teaches the labeling of human serum albumin with Tc-99m.

10 Khaw *et al.*, J. Nucl. Med. 23: 1011-1019 (1982) disclose methods for labeling biologically active macromolecules with Tc-99m.

Byrne and Tolman, *supra*, disclose a bifunctional thiolactone chelating agent for coupling Tc-99m to biological molecules.

15 Knight *et al.*, Abstract #209, 37th Annual Meeting, Society for Nuclear Medicine (1990) describe thrombus imaging with Tc-99m labeled peptides.

Cox *et al.*, Abstract, 7th International Symposium on Radiopharmacology, p. 16, 1991, disclose the use of <sup>131</sup>I- and <sup>111</sup>In-labeled somatostatin analogues in radiolocalization of endocrine tumors *in vivo* by scintigraphy.

SUMMARY OF THE INVENTION

The present invention provides scintigraphic imaging agents that are radioactively-labeled peptides. The peptides of the invention are comprised of between 4 and 100 amino acid residues, covalently linked to a radioisotope complexing group wherein the complexing group binds a radioisotope.

Preferred embodiments of the present invention are peptides that are covalently linked to radioisotope complexing groups comprising a thiol moiety having the following structure:



wherein A is H, HOOC, H<sub>2</sub>NOC, (peptide)-NHOC, (peptide)-OOC or R<sup>4</sup>; B is H, SH or -NHR<sup>3</sup>, -N(R<sup>3</sup>)-(peptide) or R<sup>4</sup>; X is SH or -NHR<sup>3</sup>, -N(R<sup>3</sup>)-(peptide) or R<sup>4</sup>; R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently H or straight or branched chain or cyclic lower alkyl; n is 0, 1 or 2; and: 1. where B is -NHR<sup>3</sup> or -N(R<sup>3</sup>)-(peptide), X is SH and n is 1 or 2; and 2. where X is -NHR<sup>3</sup> or -N(R<sup>3</sup>)-(peptide), B is SH and n is 1 or 2; 3. where B is H or R<sup>4</sup>, A is HOOC, H<sub>2</sub>NOC, (peptide)-NHOC, (peptide)-OOC, X is SH and n is 0 or 1; and 4. where A is H or R<sup>4</sup>, then where B is SH, X is -NHR<sup>3</sup> or -N(R<sup>3</sup>)-(peptide) and where X is SH, B is -NHR<sup>3</sup> or -N(R<sup>3</sup>)-(peptide); and 5. where X is H or R<sup>4</sup>, A is HOOC, H<sub>2</sub>NOC, (peptide)-NHOC, (peptide)-OOC and B is SH; and 6. where Z is methyl, X is methyl, A is HOOC, H<sub>2</sub>NOC, (peptide)-NHOC, (peptide)-OOC and B is SH and n is 0; and 7. where Z is SH and X is SH, n is not 0; and wherein the thiol moiety is in the reduced form and the complexing group is capable of being covalently linked to the peptide.

The invention encompasses peptides for labeling with Tc-99m and imaging target sites within a mammalian body comprising between 4 and 100 amino acid residues, covalently linked to a radioisotope complexing group wherein the complexing group binds a radioisotope. The invention encompasses methods for making such peptides covalently linked to a radioisotope complexing group. The invention also includes Tc-99m complexes and methods for preparation of such Tc-99m complexes and methods for using the Tc-99m complexes to image target sites within a mammalian body.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides Tc-99m labeled peptides for imaging target sites within a mammalian body that comprise between 4 and 100 amino acid residues and are covalently linked to a radioisotope complexing group wherein the complexing group binds a radioisotope.

5 Labeling with Tc-99m is an advantage of the present invention because the nuclear and radioactive properties of this isotope make it an ideal scintigraphic imaging agent. This isotope has a single photon energy of 140 keV and a radioactive half-life of about 6 hours, and is readily available from 10 a <sup>90</sup>Mo-<sup>99m</sup>Tc generator. Other radionuclides known in the prior art have effective half-lives which are much longer (for example, <sup>111</sup>In, which has a half-life of 67.4 h) or are toxic (for example, <sup>125</sup>I).

15 Peptides of the present invention can be chemically synthesized *in vitro*. Peptides of the present invention can generally advantageously be prepared on an amino acid synthesizer. The peptides of this invention can be synthesized wherein the complexing group is covalently linked to the peptide during chemical *in vitro* synthesis, using techniques well known to those with skill in the art. Such peptides covalently-linked to the complexing group upon 20 synthesis are advantageous because specific sites of covalent linkage can be determined therein.

25 In forming a complex of radioactive technetium with the peptides of this invention, the technetium complex, preferably a salt of Tc-99m pertechnetate, is reacted with the peptides of this invention in the presence of a reducing agent; in a preferred embodiment, the reducing agent is stannous chloride. In an additional preferred embodiment, the reducing agent is a solid-phase reducing agent. Complexes and means for preparing such complexes are conveniently provided in a kit form comprising a sealed vial containing a predetermined quantity of the peptides of the invention that are 30 to be labeled and a sufficient amount of reducing agent to label the peptide with Tc-99m. Alternatively, the complex may be formed by reacting the peptides of this invention with a pre-formed labile complex of technetium and another compound known as a transfer ligand. This process is known as

ligand exchange and is well known to those skilled in the art. The labile complex may be formed using such transfer ligands as tartrate, citrate, gluconate or mannitol, for example. Among the Tc-99m pertechnetate salts useful with the present invention are included the alkali metal salts such as the sodium salt, or ammonium salts or lower alkyl ammonium salts. The reaction of the peptides of this invention with Tc-pertechnetate or preformed Tc-99m labile complex can be carried out in an aqueous medium at room temperature. The anionic complex which has a charge of [-1] is formed in the aqueous medium in the form of a salt with a suitable cation such as sodium cation, ammonium cation, mono, di- or tri-lower alkyl amine cation, etc. Any conventional salt of the anionic complex with a pharmaceutically acceptable cation can be used in accordance with this invention.

In another embodiment of the present invention, the peptides of the invention that are to be labeled are reduced prior to labeling by incubating the peptides with a reducing agent. In a preferred embodiment, the reducing agent is stannous chloride. In an additional preferred embodiment, the reducing agent is a solid-phase reducing agent. The pre-reduced peptide is then labeled by reaction with a Tc-99m under reducing conditions or with pre-reduced Tc-99m or Tc-99m complex.

In a preferred embodiment of the invention, a kit for preparing technetium-labeled peptides is provided. The peptides of the invention can be chemically synthesized using methods and means well-known to those with skill in the art and described hereinbelow. Peptides thus prepared are comprised of between 4 and 100 amino acid residues, and are covalently linked to a radioisotope complexing group wherein the complexing group binds a radioisotope. An appropriate amount of the peptide is introduced into a vial containing a reducing agent, such as stannous chloride or a solid-phase reducing agent, in an amount sufficient to label the peptide with Tc-99m. An appropriate amount of a transfer ligand as described (such as tartrate, citrate, gluconate or mannitol, for example) can also be included. Technetium-labeled peptides according to the present invention can be prepared by the addition of an appropriate amount of Tc-99m or Tc-99m complex into the vials and

reaction under conditions described in Example 2 hereinbelow.

5 Radioactively labeled peptides provided by the present invention are provided having a suitable amount of radioactivity. In forming the Tc-99m radioactive anionic complexes, it is generally preferred to form radioactive complexes in solutions containing radioactivity at concentrations of from about 0.01 millicurie (mCi) to 100 mCi per ml.

10 Technetium-labeled peptides provided by the present invention can be used for visualizing organs such as the kidney for diagnosing disorders in these organs, and tumors, such as gastrointestinal tumors, myelomas, small cell lung carcinoma and other APUDomas, endocrine tumors such as medullary thyroid carcinomas and pituitary tumors, brain tumors such as meningiomas and astrocytomas, and tumors of the prostate, breast, colon, and ovaries can also be imaged. In accordance with this invention, the technetium-labeled peptides or anionic complexes either as a complex or as a 15 salt with a pharmaceutically acceptable cation are administered in a single unit injectable dose. Any of the common carriers known to those with skill in the art, such as sterile saline solution or plasma, can be utilized after radiolabeling for preparing the injectable solution to diagnostically image various organs, tumors and the like in accordance with this invention.

20 Generally, the unit dose to be administered has a radioactivity of about 0.01 mCi to about 100 mCi, preferably 1 mCi to 20 mCi. The solution to be injected at unit dosage is from about 0.01 ml to about 10 ml. After intravenous administration, imaging of the organ or tumor *in vivo* can take place in a matter of a few minutes. However, imaging can take place, if 25 desired, in hours or even longer, after injecting into patients. In most instances, a sufficient amount of the administered dose will accumulate in the area to be imaged within about 0.1 of an hour to permit the taking of scintiphotos. Any conventional method of scintigraphic imaging for diagnostic purposes can be utilized in accordance with this invention.

30 The technetium-labeled peptides and complexes provided by the invention may be administered intravenously in any conventional medium for intravenous injection such as an aqueous saline medium, or in blood plasma

medium. Such medium may also contain conventional pharmaceutical adjunct materials such as, for example, pharmaceutically acceptable salts to adjust the osmotic pressure, buffers, preservatives and the like. Among the preferred media are normal saline and plasma.

5 The methods for making and labeling these compounds are more fully illustrated in the following Examples. These Examples illustrate certain aspects of the above-described method and advantageous results. These Examples are shown by way of illustration and not by way of limitation.

10

## EXAMPLE 1

### Solid Phase Peptide Synthesis

Solid phase peptide synthesis (SPPS) was carried out on a 0.25 millimole (mmole) scale using an Applied Biosystems Model 431A Peptide Synthesizer and using 9-fluorenylmethyloxycarbonyl (Fmoc) amino-terminus protection, coupling with 2-(1H-benzo-triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate/ hydroxybenzotriazole (HBTU/HOBT), and using *p*-hydroxymethylphenoxy-methyl-polystyrene (HMP) resin for carboxyl-terminus acids or Rink amide resin for carboxyl-terminus amides. Resin-bound products were routinely cleaved using a solution comprised of trifluoroacetic acid, water, thioanisole, ethanedithiol, and triethylsilane, prepared in ratios of 100 : 5 : 5 : 2.5 : 2 for 1.5 - 3 h at room temperature. Crude peptides were purified by preparative high pressure liquid chromatography (HPLC) using a 20 Waters Delta Pak C18 column and gradient elution using 0.1% trifluoroacetic acid (TFA) in water modified with acetonitrile. Acetonitrile was evaporated from the eluted fractions which were then lyophilized. The identity of each 25 product was confirmed by fast atom bombardment mass spectroscopy (FABMS).

30

## EXAMPLE 2

### A General Method for Radiolabeling with Tc-99m

0.1 mg of a peptide prepared as in Example 1 was dissolved in 0.1 ml

of 0.05M potassium phosphate buffer (pH 7.4). Tc-99m gluceptate was prepared by reconstituting a Glucoscan vial (E.I. DuPont de Nemours, Inc.) with 1.0 ml of Tc-99m sodium pertechnetate containing up to 200 mCi and allowed to stand for 15 minutes at room temperature. 25  $\mu$ l of Tc-99m gluceptate was then added to the peptide and the reaction allowed to proceed at room temperature for 30 min and then filtered through a 0.2  $\mu$ m filter.

The Tc-99m labeled peptide purity was determined by HPLC using a Vydak 218TP54 analytical column (RP-18, 5 micron, 220 x 4.6 mm) and eluted with the following gradient: 100% A (0.1% TFA in H<sub>2</sub>O) to 100% B (CH<sub>3</sub>CN:H<sub>2</sub>O:TFA, 70:30:0.1) over 10 minutes at a flow rate of 1.2 ml/min; and then held at the 100% B solution for 5 minutes. Radioactive components were detected by an in-line radiometric detector linked to an integrating recorder. Tc-99m gluceptate and Tc-99m sodium pertechnetate elute between 1 and 4 minutes under these conditions, whereas the Tc-99m labeled peptide eluted after a much greater amount of time.

The following Table illustrates successful Tc-99m labeling of peptides prepared according to Example 1 using the method described herein.

It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims.

TABLE I

Peptides Prepared and Radiolabeled	FABMS MH+ Found/Theoretical	Radiochemical Yield	HPLC Rt (min)
YRALVDTLKVFTQABGAKC-NH <sub>2</sub>	2113/2113.1	92%	11-15.5
GRGDGQC	769/768.3	98%	13-15
5 maGGGRGDF*	739/739.3	98%	13-15
PENGGRALVDTLK-NH <sub>2</sub> *	1216.3/1216.7	98%	14.8
maGGGGRALVDTLK-NH <sub>2</sub>	1160/1160.5	97%	14.3
mmpGGGRALVDTLK-NH <sub>2</sub> *	1187.4/1186.7	98%	14.9-15.5

10 \* ma = mercaptoacetic acid

\* Pen = L-penicillamine

\* mmp = 2-mercapto-2-methylpropionic acid

**What is claimed is:**

1. A peptide capable of being radioactively-labeled for imaging target sites within a mammalian body, wherein the peptide is comprised of between 4 and 100 amino acid residues and is covalently linked to a complexing group comprising a thiol moiety that is:



10       wherein       A is H, HOOC, H<sub>2</sub>NOC, (peptide)-NHOC, (peptide)-OOC or R<sup>4</sup>;

15       B is H, SH, -NHR<sup>3</sup>, -N(R<sup>3</sup>)-(peptide), or R<sup>4</sup>;

20       X is H, SH, -NHR<sup>3</sup>, -N(R<sup>3</sup>)-(peptide) or R<sup>4</sup>;

25       Z is H or R<sup>4</sup>;

30       R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently H or lower straight or branched chain or cyclic alkyl;

35       n is 0, 1 or 2;

40       and  
where B is -NHR<sup>3</sup> or -N(R<sup>3</sup>)-(peptide), X is SH, and n is 1 or 2;  
where X is -NHR<sup>3</sup> or -N(R<sup>3</sup>)-(peptide), B is SH, and n is 1 or 2;  
where B is H or R<sup>4</sup>, A is HOOC, H<sub>2</sub>NOC, (peptide)-NHOC, (peptide)-OOC,  
X is SH, and n is 0 or 1;  
where A is H or R<sup>4</sup>, then where B is SH, X is -NHR<sup>3</sup> or -N(R<sup>3</sup>)-(peptide) and  
where X is SH, B is -NHR<sup>3</sup> or -N(R<sup>3</sup>)-(peptide);  
where X is H or R<sup>4</sup>, A is HOOC, H<sub>2</sub>NOC, (peptide)-NHOC, (peptide)-OOC  
and B is SH;  
where Z is methyl, X is methyl, A is HOOC, H<sub>2</sub>NOC, (peptide)-NHOC,  
(peptide)-OOC, B is SH and n is 0;  
where B is SH and X is SH, n is not 0;  
and wherein the thiol moiety is in the reduced form and the complexing group  
is capable of being covalently linked to the peptide.

2. The peptide according to Claim 1 wherein the peptide region and the complexing group are covalently linked through one or more amino acids.

5 3. The peptide according to Claim 1 wherein the complexing group is bound to a radioactive isotope.

10 4. The peptide of Claim 3 wherein the radioactive isotope is Tc-99m.

15 5. A complex formed by reacting a peptide according to Claim 1 with Tc-99m in the presence of a reducing agent.

6. The complex of Claim 5, wherein the reducing agent is selected from the group of a dithionite ion, a stannous ion, or a solid-phase reducing agent.

7. A complex formed by labeling a peptide according to Claim 1 with Tc-99m by ligand exchange of a prereduced Tc-99m complex.

20 8. A composition of matter comprising the peptide according to Claim 1 and a stannous ion.

25 9. A kit for preparing a radiopharmaceutical preparation, said kit comprising sealed vial containing a predetermined quantity of a peptide according to Claim 1 and a sufficient amount of reducing agent to label said compound with Tc-99m.

30 10. A method for labeling a peptide according to Claim 1 comprising reacting the peptide with Tc-99m in the presence of a reducing agent.

11. The method of Claim 10, wherein the reducing agent is selected from the group of a dithionite ion, a stannous ion, or a solid-phase reducing agent.

5

12. A method for imaging a target site within a mammalian body comprising administering an effective diagnostic amount of a peptide according to Claim 1 which is labeled with Tc-99m and wherein the peptide binds to the target site, and detecting the localized Tc-99m.

10

13. The peptide according to Claim 1 wherein the peptide is chemically synthesized *in vitro*.

14. The peptide according to Claim 13 wherein the peptide is synthesized by solid phase peptide synthesis.

15

15. The peptide according to Claim 13 wherein the complexing group is covalently linked to the peptide during *in vitro* chemical synthesis.

20

16. The peptide according to Claim 14 wherein the complexing group is covalently linked to the peptide during solid phase peptide synthesis.

25

17. A peptide according to Claim 1 having the formula:

HS-CH<sub>2</sub>-CO-GGGRALVDTLKFVTQAE<sup>G</sup>A<sup>K</sup>.amide